Overview

CancerFax issued a press release on July 13, 2026, from New Delhi announcing that it is strengthening its end‑to‑end patient‑navigation support for Indian and international patients who are exploring advanced oncology treatment options at leading hospitals in China. The announcement stresses a focus on hospital‑based medical evaluation and responsible access, aiming to bring structure and transparency to a process that many patients find confusing.

Advanced Oncology Landscape in China

The release notes that China has become a prominent centre for advanced oncology therapies, including cancer gene therapy, CAR‑T cell therapy, immunotherapy, advanced radiotherapy, and clinical‑trial programmes. It references the early approval of Gendicine, a recombinant human p53 adenovirus gene therapy, and highlights ongoing research in solid‑tumour CAR‑T targets such as Claudin18.2, GPC3, B7‑H3 and CEA, as well as tumour‑infiltrating lymphocyte (TIL) therapy. Specialized Chinese centres also provide proton and heavy‑ion therapy, and interventional oncology techniques such as TACE, TARE, HIFU and ablation. For patients who have exhausted standard options, clinical‑trial matching may be an important pathway.

Patient Navigation Services

CancerFax’s platform supports the full patient journey. Services include coordination of medical‑report review, preparation of case summaries, matching patients with appropriate hospitals or departments, arranging expert second opinions, checking preliminary eligibility, providing treatment‑cost guidance, scheduling appointments, coordinating hospital admission, assisting with visa documentation, offering travel‑and‑stay guidance, delivering translation and interpretation support, and managing post‑treatment follow‑up. The company stresses that advanced therapies are not suitable for every patient and must be assessed case‑by‑case based on cancer type, disease stage, biomarkers, prior treatment history, organ function, performance status and hospital review.

Regulatory / Medical Disclaimer

CancerFax explicitly states that it does not make treatment promises, does not make medical decisions, and that final treatment decisions, eligibility assessments and medical recommendations rest with qualified doctors and hospitals after detailed evaluation of each patient’s records. The platform emphasizes verified hospital communication, transparent cost coordination and ethical navigation, advising patients not to travel without proper medical evaluation.

Leadership Statement

Founder and CEO Sandeep Kumar Wamne said, “Many patients and families hear about advanced treatment options in China, but they do not know where to begin, which hospital to approach, or whether they are even eligible. Our role at CancerFax is to bring structure, transparency, and medical responsibility to that journey, so that patients can make informed decisions with the right hospital teams.”

About CancerFax

CancerFax describes itself as an international cancer‑treatment navigation platform that helps patients and families access expert opinions, advanced treatment options and hospital‑based care coordination across leading cancer centres in India, China and other global destinations. The platform’s services mirror those listed above and it reiterates that it does not provide medical treatment, replace medical advice, or guarantee outcomes; suitability and eligibility are determined by qualified doctors after comprehensive evaluation of diagnosis, disease status, biomarkers, prior treatment, performance status, organ function and overall health.

Media Contact

WhatsApp: +1 213 789 56 55

WeChat: +86 182 1759 2149

The press release is distributed under an arrangement with PRNewswire; PTI takes no editorial responsibility.